20 Dec, EOD - Indian

SENSEX 78041.59 (-1.49)

Nifty 50 23587.5 (-1.52)

Nifty Bank 50759.2 (-1.58)

Nifty IT 43771.05 (-2.63)

Nifty Midcap 100 56906.75 (-2.82)

Nifty Next 50 68702.65 (-2.72)

Nifty Pharma 22501.85 (-0.86)

Nifty Smallcap 100 18714.3 (-2.19)

20 Dec, EOD - Global

NIKKEI 225 38701.9 (-0.29)

HANG SENG 19720.7 (-0.16)

S&P 6008.5 (1.05)

Login/Signup
LOGIN HERE
Cancel

Zydus Lifesciences Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 532321 | NSE Symbol : ZYDUSLIFE | ISIN : INE010B01027 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
30-Oct-2024 12-Nov-2024 Quarterly Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited financial results for the quarter and half year ended on September 30 2024. Unaudited financial results for the quarter and half year ended on September 30, 2024 Unaudited financial results for the quarter and half year ended on September 30, 2024 (As Per BSE Announcement Dated on 12.11.2024)
18-Jul-2024 09-Aug-2024 Quarterly Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2024. Unaudited Financial results for the quarter ended June 30, 2024 (As Per BSE Announcement dated on 09.08.2024)
09-May-2024 17-May-2024 Accounts Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve audited financial results for the quarter and year ended on March 31 2024 Final dividend The Board of Directors at their meeting held today have recommended final dividend of Rs.3.00/- (@300%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 9, 2024 Appointment of Independent Director (As Per BSE Announcement Dated on 17.05.2024)
29-Jan-2024 09-Feb-2024 Quarterly Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 inter alia to consider and approve Unaudited Financial Results for the quarter / nine months ended on December 31 2023. Buyback of shares Buyback of shares Record date of buyback: February 23, 2024 Unaudited financial results for the quarter and nine months ended on December 31, 2023 Buyback of shares (As Per BSE Announcement Dated on 09.02.2024) Newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter / nine months ended on December 31, 2023 in Financial Express on February 10, 2024. (As Per BSE Announcement Dated on 10.02.2024)
30-Oct-2023 07-Nov-2023 Quarterly Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve the unaudited financial results for the quarter / half year ended on September 30 2023. Unaudited Financial Results for the quarter / half year ended on September 30, 2023 Unaudited Financial Results for the quarter / half year ended on September 30, 2023 (As Per BSE Announcement Dated on 07.11.2023)
31-Jul-2023 11-Aug-2023 Quarterly Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the unaudited financial results for the quarter ended on June 30 2023. Unaudited Financial Results for the quarter ended on June 30, 2023 Unaudited Financial Results for the quarter ended on June 30, 2023 (As Per BSE Announcement Dated on 11.08.2023)
12-May-2023 18-May-2023 Accounts Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2023 inter alia to consider and approve apart from other agenda items approval of audited financial results for the quarter / year ended on March 31 2023 and to recommend final dividend for the financial year ended on March 31 2023. Outcome of Board meeting Re-appointment of Independent Director of the Company (As per BSE Announcement Dated on 18/05/2023)
23-Jan-2023 03-Feb-2023 Quarterly Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve unaudited financial results for the quarter / nine months ended on December 31 2022. The Board of Directors at their meeting held today i.e. February 3, 2023, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / nine months ended on December 31, 2022. (As per BSE Announcement Dated on 03/02/2023)
29-Nov-2022 29-Nov-2022 Change in Directors Appointment of two Independent Directors
31-Oct-2022 11-Nov-2022 Quarterly Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve approval of unaudited financial results for the quarter / half year ended on September 30 2022. The Board of Directors at their meeting held today i.e. November 11, 2022, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / half year ended on September 30, 2022. (As Per BSE Announcement dated on 11.11.2022)
03-Aug-2022 10-Aug-2022 Quarterly Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2022 Approval of the unaudited financial results for the quarter ended on June 30, 2022 (As Per BSE Announcement dated on 10.08.2022)
13-May-2022 20-May-2022 Accounts Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 inter alia to consider and approve The meeting of the Board of Directors of the Company will be held on Friday May 20 2022 to consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31 2022 and to recommend final dividend for the financial year ended on March 31 2022 Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 ,inter alia, to consider and approve Update on board meeting. Board will also consider the proposal to buyback equity shares of the Company. With reference to the earlier letter dated May 13, 2022 intimating about the meeting of the Board of Directors of the Company scheduled to be held on May 20, 2022. Zydus Lifesciences Ltd has now informed BSE that the Board of Directors of the Company, at its aforesaid meeting, will also consider a proposal for buyback of fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the applicable provisions under the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws. (As Per BSE Announcement Dated on 17.05.2022) Board approves the dividend Intimation of Record Date Buy Back of Shares Annual Audited financial results for the financial year ended on March 31, 2022 (As Per BSE Announcement Dated on 20.05.2022) The Board of Directors at their meeting held today have recommended final dividend of Rs. 2.50/- (@ 250%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 10, 2022. Re-appointment of Deloitte as the Statutory Auditors subject to the approval of the shareholders at the ensuing annual general meeting (As Per BSE Bulletin Dated on 20.05.2022)
25-Jan-2022 03-Feb-2022 Quarterly Results CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2022 inter alia to consider and approve Approval of the unaudited financial results for the quarter / nine months ended on December 31 2021 The unaudited financial results (standalone and consolidated) for the quarter / nine months ended on December 31, 2021 (As Per BSE Announcement dated on 03.02.2022)
21-Jan-2022 21-Jan-2022 Change in Directors Re-appointment of Dr. Sharvil P. Patel as the Managing Director subject to approval of shareholders.
20-Oct-2021 29-Oct-2021 Quarterly Results Quarterly Results Unaudited Financial Results for the quarter / half year ended on September 30, 2021 (As Per BSE Announcement dated on 29.10.2021)
1 2